EZHARMIA® Receives Approval in Japan as the First Dual EZH1 and EZH2 Blocker for Peripheral T-Cell Lymphoma Therapy.

vTv Therapeutics Announces Enrollment of First Participant in CATT1 Key Study for Cadisegliatin in Type 1 Diabetes.

TiumBio Unveils Promising Initial Clinical Data for TU7710, Its Hemophilia Therapy Candidate, at ISTH 2024.

The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.

Innovent Unveils Phase 3 Study Outcomes of Mazdutide for Weight Control at the ADA's 84th Scientific Sessions.

The European Commission has approved Roche's OCREVUS for subcutaneous use, making it the first and only twice-yearly injection for relapsing and primary progressive multiple sclerosis.

Alnylam Announces Successful Topline Results from HELIOS-B Phase 3 Trial of Vutrisiran, Showing Statistical Significance in Primary and All Secondary Endpoints in Both Combined and Monotherapy Groups.

This IND will enable the assessment of ADI-270, for the therapeutic intervention in relapsed/refractory renal cell carcinoma.

Scholar Rock Unveils New SRK-439 Preclinical Data Showing Notable Lean Mass Preservation and Reduced Fat Mass Rebound After Stopping GLP-1 Receptor Agonist.

Altimmune Shares Findings on Pemvidutide's Impact on Cardioinflammatory Lipid Levels at ADA’s 84th Annual Scientific Sessions.

Novo Nordisk A/S: Mim8 showed better reductions in annual bleeding rates (ABR) than on-demand treatments and previous prophylaxis in haemophilia A patients.

In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.